10 completed, 4 terminated, 3 unknown, 1 not yet recruiting. 11 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Completed 5, Terminated 4, Not yet recruiting 1, Unknown 1 |
| Phase 1 | 4 | Completed 1, Not yet recruiting 1, Terminated 1, Unknown 1 |
Follow Armando Santoro, MD: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Niraparib and Temozolomide in Patients Glioblastoma Temodal, Niraparib - Glioma, Malignant | Phase 1 / Phase 2 | Not yet recruiting | Armando Santoro, MD | 86 | 2024-09-01 | 2024-08-30 |
| Anti-Mullerian Hormone (AMH) as Marker of Ovarian Reserve Triptorelin - Breast Cancer | Phase 2 | Terminated | Armando Santoro, MD | 45 | 2013-05-01 | 2022-09-10 |
| Study of Tivantinib (ARQ 197) Plus Cetuximab in EGFR Inhibitor-Resistant MET High Subjects Tivantinib (ARQ197) - Colorectal Cancer Metastatic, C-met Overexpression | Phase 2 | Completed | Armando Santoro, MD | 43 | 2013-03-01 | 2022-09-09 |
| Study of the Combination of Tivantinib Plus Pemetrexed and Carboplatin Tivantinib - Malignant Pleural Mesothelioma, Nonsquamous Nonsmall Cell Neoplasm of Lung | Phase 1 / Phase 2 | Completed | Armando Santoro, MD | 31 | 2013-01-01 | 2021-01-22 |
| Pharmacogenetics Of Vinorelbine In Malignant Pleural Mesothelioma Patients Malignant Pleural Mesothelioma | Completed | Armando Santoro, MD | 150 | 2012-11-01 | 2022-09-10 | |
| Bendamustine, Gemcitabine and Vinorelbine (BeGEV) as Induction Therapy in Relapsed/Refractory Hodgkin's Lymphoma Patients Bendamustine, Gemcitabine, Vinorelbine - Hodgkin's Lymphoma | Phase 2 | Unknown | Armando Santoro, MD | 59 | 2011-07-01 | 2014-01-29 |
| Study of Combination of PIGEV Before Autologous Stem Cell Transplant in Patients With Hodgkin's Lymphoma panobinostat, Ifosfamide, Gemcitabine - Hodgkin's Lymphoma | Phase 1 | Unknown | Armando Santoro, MD | 24 | 2011-07-01 | 2014-01-29 |
| Observational Prospective Analysis of Biological Characteristics of Mesothelioma Patients Malignant Mesothelioma | Completed | Armando Santoro, MD | 100 | 2011-04-01 | 2022-09-09 | |
| Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy Everolimus - Thymoma and Thymic Carcinoma | Phase 2 | Completed | Armando Santoro, MD | 41 | 2011-02-01 | 2022-09-10 |
| Evaluation of Immunological Reconstitution After Haploidentical Bone Marrow Transplantation Lymphoma | Unknown | Armando Santoro, MD | 23 | 2011-01-01 | 2013-07-03 | |
| Pemetrexed in Advanced Non-small Cell Lung Cancer Non-small Cell Lung Cancer (NSCLC) | Completed | Armando Santoro, MD | 33 | 2010-09-01 | 2022-09-10 | |
| Study of Oral Vorinostat in Combination With Topotecan in Patients With Chemosensitive Recurrent SCLC topotecan, vorinostat - Small Cell Lung Cancer | Phase 1 / Phase 2 | Terminated | Armando Santoro, MD | 2 | 2009-01-01 | 2013-05-29 |
| Mono Versus Polichemotherapy in Non Small Cell Lung Cancer (NSCLC) Elderly Patients Pemetrexed/Carboplatin, Gemcitabine - NSCLC | Phase 2 | Terminated | Armando Santoro, MD | 108 | 2008-10-01 | 2022-09-10 |
| Identification of EGFR-TKIs Sensitivity or Resistance Markers in NSCLC May Help in Optimal Patient Selection NON-SMALL-CELL LUNG CANCER | Completed | Armando Santoro, MD | 51 | 2008-09-01 | 2014-12-02 | |
| Trastuzumab Therapy in Non-Small Cell Lung Cancer Patients Trastuzumab (Herceptin) - NON-SMALL CELL LUNG CANCER | Phase 2 | Terminated | Armando Santoro, MD | 9 | 2008-07-01 | 2013-05-29 |
| Retrospective Study Evaluating IGF1R And p95HER2 as Prognostic Factors in Non Small Cell Lung Cancer (NSCLC) Protein expression by immunohistochemistry and immunofluorescence - Non Small Cell Lung Cancer | Completed | Armando Santoro, MD | 454 | 2007-11-01 | 2022-09-10 | |
| Phase II Study of Bevacizumab, Pemetrexed and Carboplatin as First-Line Therapy in Malignant Pleural Mesothelioma Bevacizumab, Pemetrexed, Carboplatin - Mesothelioma | Phase 2 | Completed | Armando Santoro, MD | 77 | 2007-09-01 | 2011-09-02 |
| Pegfilgrastim Versus Filgrastim After High-dose Chemotherapy Filgrastim, Pegfilgrastim - Hematological Neoplasms, Tumors | Phase 2 | Completed | Armando Santoro, MD | 80 | 2006-09-01 | 2013-07-01 |
Carcinoma, Non-Small-Cell Lung (4) · Lymphoma (3) · Mesothelioma, Malignant (3) · Hodgkin Disease (2) · Breast Neoplasms (1) · Glioma (1) · Hematologic Neoplasms (1) · Mesothelioma (1) · Neoplasms (1) · Recurrence (1) · Small Cell Lung Carcinoma (1) · Thymoma (1)
Gemcitabine (3) · ARQ 197 (2) · Carboplatin (2) · Pemetrexed (2) · Vinorelbine (2) · Bendamustine Hydrochloride (1) · Bevacizumab (1) · Cetuximab (1) · Everolimus (1) · Filgrastim (1) · Fluorescent Antibody Technique (1) · Ifosfamide (1) · Methylprednisolone (1) · Panobinostat (1) · Prednisolone (1)
Italy (18)
Lorenza Rimassa, MD (1) · Matteo Simonelli, MD (1)
PMID 20007996, PMID 23860535, PMID 27382096, PMID 29240542, PMID 31935284
2008 (1)